Press Release: Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER(R) IMA402 Targeting PRAME

Dow Jones
2024-11-18
    equity                                                             (2,039) 
   Repayments related to lease 
    liabilities                                   (1,228)              (2,877) 
 
   Net cash provided by financing 
    activities                                    173,326               85,488 
 
   Net decrease in cash and cash 
    equivalents                                  (31,208)             (66,486) 
 
   Cash and cash equivalents at 
    beginning of the year                         218,472              148,519 
 
   Effects of exchange rate changes, 
    expected credit losses and 
    accrued interest on cash and 
    cash equivalents                                1,935                1,413 
 
   Cash and cash equivalents at end 
    of the year                                   189,199               83,446 
 
 

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Changes in Shareholders' Equity of Immatics N.V.

 
                                                                                                             Total 
                                                                                                             share- 
                              Share              Share             Accumulated            Other             holders' 
  (Euros in thousands)       capital            premium              deficit             reserves            equity 
   Balance as of 
    January 1, 2023                 767              714,177            (500,299)            (1,481)             213,164 
   Other comprehensive 
    income                           --                   --                   --                769                 769 
   Net loss                          --                   --             (70,846)                 --            (70,846) 
   Comprehensive loss 
    for the year                     --                   --             (70,846)                769            (70,077) 
   Equity-settled 
    share-based 
    compensation                     --               16,299                   --                 --              16,299 
   Share options 
    exercised                        --                  140                   --                 --                 140 
   Issue of share 
    capital -- net of 
    transaction costs                80               88,145                   --                 --              88,225 
 
   Balance as of 
    September 30, 
    2023                            847              818,761            (571,145)              (712)             247,751 
 
   Balance as of 
    January 1, 2024                 847              823,166            (597,293)            (1,636)             225,084 
   Other comprehensive 
    income                           --                   --                   --              $(579.SI)$               (579) 
   Net loss                          --                   --             (29,645)                 --            (29,645) 
   Comprehensive loss 
    for the year                     --                   --             (29,645)              (579)            (30,224) 
   Equity-settled 
    share-based 
    compensation                     --               13,112                   --                 --              13,112 
Share options 
 exercised                            1                1,113                   --                 --               1,114 
   Issue of share 
    capital -- net of 
    transaction costs               183              173,257                   --                 --             173,440 
 
   Balance as of 
    September 30, 
    2024                          1,031            1,010,648            (626,938)            (2,215)             382,526 
 
 

(1) All amounts translated using the exchange rate published by the European Central Bank in effect as of September 30, 2024 (1 EUR = 1.1196 USD).

Attachment

 

(MORE TO FOLLOW) Dow Jones Newswires

November 18, 2024 07:00 ET (12:00 GMT)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10